BLACK DIAMOND THERAPEUTICS, INC. Operating Cash Flow
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Operating Cash Flow of -$18.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.97M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.23M, a 119.16% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.79M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.85M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $29.61M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$62.30M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$66.72M.
- BLACK DIAMOND THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$85.08M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$18.20M 10-Q · filed 2026-08-05 | -$24.99M derived: sum of 3 quarters · filed 2026-08-05 | -$32.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$10.23M 10-Q · filed 2026-05-07 | -$17.02M derived: sum of 2 quarters · filed 2026-05-07 | -$24.87M derived: sum of 3 quarters · filed 2026-05-07 | -$34.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$14.64M derived: sum of 2 quarters · filed 2026-03-16 | -$23.80M derived: sum of 3 quarters · filed 2026-08-05 | $29.61M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$7.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$17.01M derived: sum of 2 quarters · filed 2026-08-05 | $36.40M 10-Q · filed 2025-11-06 | $21.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$9.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $44.25M 10-Q · filed 2026-08-05 | $29.20M derived: sum of 3 quarters · filed 2026-08-05 | $17.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $53.41M 10-Q · filed 2026-05-07 | $38.35M derived: sum of 2 quarters · filed 2026-05-07 | $27.03M derived: sum of 3 quarters · filed 2026-05-07 | $12.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$15.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$26.38M derived: sum of 2 quarters · filed 2026-03-16 | -$41.10M derived: sum of 3 quarters · filed 2026-03-16 | -$62.30M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$26.05M derived: sum of 2 quarters · filed 2025-11-06 | -$47.25M 10-Q · filed 2025-11-06 | -$61.20M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$14.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$35.92M 10-Q · filed 2025-08-07 | -$49.88M derived: sum of 3 quarters · filed 2025-08-07 | -$68.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$21.20M 10-Q · filed 2025-05-12 | -$35.16M derived: sum of 2 quarters · filed 2025-05-12 | -$53.52M derived: sum of 3 quarters · filed 2025-05-12 | -$67.89M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$32.32M derived: sum of 2 quarters · filed 2025-03-06 | -$46.69M derived: sum of 3 quarters · filed 2025-03-06 | -$66.72M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$18.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$32.73M derived: sum of 2 quarters · filed 2024-11-05 | -$52.76M 10-Q · filed 2024-11-05 | -$74.70M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$14.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$34.40M 10-Q · filed 2024-08-06 | -$56.34M derived: sum of 3 quarters · filed 2024-08-06 | -$72.81M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$20.03M 10-Q · filed 2024-05-09 | -$41.97M derived: sum of 2 quarters · filed 2024-05-09 | -$58.45M derived: sum of 3 quarters · filed 2024-05-09 | -$76.51M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$21.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$38.41M derived: sum of 2 quarters · filed 2024-03-12 | -$56.48M derived: sum of 3 quarters · filed 2024-03-12 | -$85.08M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$16.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$34.54M derived: sum of 2 quarters · filed 2023-11-06 | -$63.14M 10-Q · filed 2023-11-06 | -$87.19M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$18.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$46.67M 10-Q · filed 2023-08-11 | -$70.71M derived: sum of 3 quarters · filed 2023-08-11 | -$97.19M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$28.60M 10-Q · filed 2023-05-09 | -$52.65M derived: sum of 2 quarters · filed 2023-05-09 | -$79.13M derived: sum of 3 quarters · filed 2023-05-09 | -$104.29M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$24.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$50.53M derived: sum of 2 quarters · filed 2023-03-09 | -$75.69M derived: sum of 3 quarters · filed 2023-03-09 | -$100.15M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$26.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$51.65M derived: sum of 2 quarters · filed 2022-11-08 | -$76.10M 10-Q · filed 2022-11-08 | -$91.88M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$25.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$49.62M 10-Q · filed 2022-08-09 | -$65.39M derived: sum of 3 quarters · filed 2022-08-09 | -$76.88M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$24.45M 10-Q · filed 2022-05-11 | -$40.23M derived: sum of 2 quarters · filed 2022-05-11 | -$51.72M derived: sum of 3 quarters · filed 2022-05-11 | -$65.28M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$15.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$27.26M derived: sum of 2 quarters · filed 2022-03-17 | -$40.83M derived: sum of 3 quarters · filed 2022-03-17 | -$52.15M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$11.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$25.05M derived: sum of 2 quarters · filed 2021-11-08 | -$36.37M 10-Q · filed 2021-11-08 | -$43.86M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$13.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$24.89M 10-Q · filed 2021-08-12 | -$32.37M derived: sum of 3 quarters · filed 2021-08-12 | -$37.68M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$11.32M 10-Q · filed 2021-05-07 | -$18.80M derived: sum of 2 quarters · filed 2021-05-07 | -$24.11M derived: sum of 3 quarters · filed 2021-05-07 | -$29.11M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$12.80M derived: sum of 2 quarters · filed 2021-03-25 | -$17.80M derived: sum of 3 quarters · filed 2021-03-25 | -$24.67M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$5.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$10.31M derived: sum of 2 quarters · filed 2020-11-10 | -$17.19M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$11.88M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$6.88M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$8.45M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |